Medical Therapy. Efficacy or Lack of Efficacy

Continuous Prostanoid Initiation in Severe Pulmonary Hypertension in the Pediatric Cardiac Intensive Care Unit

Richard U. Garcia, Asaad Beshish, Arene Butto, Usama Kanaan, Kevin MaherEmory University School of Medicine and Children’s Healthcare of Atlanta.United States Pediatric CardiologyPediatr Cardiol 2023; DOI: 10.1007/s00246-023-03282-y AbstractObjective: Limited data exists regarding prostanoid (PGI2) use in critically ill patients with pulmonary hypertension. (PH) in the pediatric cardiac intensive care unit (CICU) setting.Materials and methods: Single center, retrospective study […]

Continuous Prostanoid Initiation in Severe Pulmonary Hypertension in the Pediatric Cardiac Intensive Care Unit Read More »

Intrastent sonotherapy in pulmonary vein restenosis: a new treatment for a recalcitrant problem

C. J. McMahon, C. E. Mullins, H. G. El SaidTexas Children’s Hospital, Baylor College of MedicineUnited States HeartHeart 2003; 89: E6DOI: 10.1136/heart.89.2.e6 AbstractA 2 year old boy developed recurrent pulmonary vein stenosis after surgical repair of infradiaphragmatic pulmonary venous connection. He had required implantation of stents in the left and right sided pulmonary veins at 7

Intrastent sonotherapy in pulmonary vein restenosis: a new treatment for a recalcitrant problem Read More »

Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration

Jenna M. Faircloth, Neelam D. Bhatt, Corey A. Chartan, Ryan D. Coleman, Natalie Villafranco, Fadel E. Ruiz, Raysa Morales-Demori, Elise Whalen, Erin Ely, Rozmeen Fombin, Nidhy P. VargheseTexas Children’s Hospital and Baylor College of Medicine.United States Frontiers in PediatricsFront Pediatr 2023; 11DOI: 10.3389/fped.2023.1275389 AbstractThis corrects the article DOI: 10.3389/fped.2023.1050508. CategoryClass I. Idiopathic Pulmonary HypertensionClass I. Heritable

Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration Read More »

The small-molecule formyl peptide receptor biased agonist, Compound 17b, is a vasodilator and anti-inflammatory in mouse precision-cut lung slices

William R. Studley, Emma Lamanna, Katherine A. Martin, Claudia A. Nold-Perry, Simon G. Royce, Owen L. Woodman, Rebecca H. Ritchie, Cheng Xue Qin, Jane E. BourkeMonash University. Hudson Institute of Medical Research. Baker Heart and Diabetes Institute.Australia British Journal of PharmacologyBr J Pharmacol 2023; DOI: 10.1111/bph.16231 AbstractBackground and purpose: Pulmonary arterial hypertension (PAH), a rare but fatal

The small-molecule formyl peptide receptor biased agonist, Compound 17b, is a vasodilator and anti-inflammatory in mouse precision-cut lung slices Read More »

Prevalence of malnutrition in pediatric pulmonary hypertension cohort and role for registered dietitian involvement

Presley R. Crowell, Mackenzie R. Frederick, Rozmeen A. Fombin, Nidhy P. Varghese, Fadel E. RuizTexas Children’s Hospital and Baylor College of Medicine.United States Frontiers in PediatricsFront Pediatr 2023; 11DOI: 10.3389/fped.2023.995470 AbstractIntroduction: Pediatric pulmonary hypertension (PH) is a serious condition with increased risk for malnutrition due to increased caloric needs and reduced energy intake. This combination of disease

Prevalence of malnutrition in pediatric pulmonary hypertension cohort and role for registered dietitian involvement Read More »

Elastin stabilization prevents impaired biomechanics in human pulmonary arteries and pulmonary hypertension in rats with left heart disease

Mariya M. Kucherenko, Pengchao Sang, Juquan Yao, Tara Gransar, Saphala Dhital, Jana Grune, Szandor Simmons, Laura Michalick, Dag Wulsten, Mario Thiele, Orr Shomroni, Felix Hennig, Ruhi Yeter, Natalia Solowjowa, Gabriela Salinas, Georg N. Duda, Volkmar Falk, Naren R. Vyavahare, Wolfgang M. Kuebler, Christoph KnosallaDeutsches Herzzentrum der Charité. Charité-Universitätsmedizin Berlin. Freie Universität Berlin and Humboldt-Universität zu

Elastin stabilization prevents impaired biomechanics in human pulmonary arteries and pulmonary hypertension in rats with left heart disease Read More »

Inhaled nitric oxide use in newborns

Souvik Mitra, Gabriel AltitCanadian Paediatric Society.Canada Paediatrics and Child HealthPaediatr Child Health 2023; 28: 119-127DOI: 10.1093/pch/pxac107 AbstractInhaled nitric oxide (iNO), a selective pulmonary vasodilator, is used as a therapeutic modality in infants with hypoxemic respiratory failure (HRF) associated with persistent pulmonary hypertension of the newborn (PPHN). iNO should ideally be initiated following echocardiographic confirmation of PPHN.

Inhaled nitric oxide use in newborns Read More »

Intravenous sildenafil for treatment of early pulmonary hypertension in preterm infants

Lukas Schroeder, Paulina Monno, Brigitte Strizek, Till Dresbach, Andreas Mueller, Florian KipfmuellerUniversity Children’s Hospital Bonn and University Hospital Bonn.Germany Scientific ReportsSci Rep 2023; 13DOI: 10.1038/s41598-023-35387-y AbstractData is lacking on the effect of continuous intravenous sildenafil treatment in preterm infants with early pulmonary hypertension (PH), especially in very low birth weight (VLBW) infants. Preterm infants (< 37

Intravenous sildenafil for treatment of early pulmonary hypertension in preterm infants Read More »

Severe Pulmonary Arterial Hypertension in Healthy Young Infants: Single Center Experience

Shrikiran Aroor, Koushik Handattu, Suneel C. Mundkur, Aditya Verma, Praveen C. Samuel, Akkatai S. Teli, Gujan BangaKasturba Medical College. India Indian PediatricsIndian Pediatr 2023; AbstractObjectives: We studied the clinical presentation and management of acute pulmonary arterial hypertension (PAH) in healthy young infants, and the effect thiamine therapy.Methods: Review of hospital records was conducted for 56 healthy infants

Severe Pulmonary Arterial Hypertension in Healthy Young Infants: Single Center Experience Read More »

Macitentan in the Young-Mid-term Outcomes of Patients with Pulmonary Hypertensive Vascular Disease treated in a Pediatric Tertiary Care Center

Sulaima Albinni, Julian Heno, Imre Pavo, Erwin Kitzmueller, Manfred Marx, Ina Michel‑BehnkeMedical University of Vienna.Austria Paediatric DrugsPaediatr Drugs 2023; 25: 467-481DOI: 10.1007/s40272-023-00573-y AbstractBackground: Pulmonary hypertension (PH) is a severe hemodynamic condition with high morbidity and mortality. Approved targeted therapies are limited for pediatric subjects, and treatments are widely adopted from adult algorithms. Macitentan is a safe and effective drug used for adult PH,

Macitentan in the Young-Mid-term Outcomes of Patients with Pulmonary Hypertensive Vascular Disease treated in a Pediatric Tertiary Care Center Read More »

Scroll to Top